All In Biotech

Drug Trial Radar · NCT01549223

Oxytocin And Uterotonic Agent Use For Cesarean Delivery

A Randomized Controlled Trial of Standardized Versus Conventional Oxytocin and Uterotonic Agent Use for Cesarean Delivery

Last checked: Nov 20, 2026Latest source record: Jun 29, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

60

Actual

Start

Apr 2011

Primary completion

Jan 2012

Study completion Jan 2012

Sponsor

Lead sponsor
Brigham and Women's HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 9, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The central objective of this study will be to evaluate a standardized, evidence-based regimen versus a conventional regimen for uterotonic drug dosing for elective cesarean delivery The investigators primary hypothesis is that the proposed uterotonic drug regimen, when compared to conventional dosing regimen, during elective cesarean delivery will: 1\. Reduce the overall amount of oxytocin and other uterotonic agents used to obtain satisfactory uterine tone. Secondary outcomes to be evaluated will be: 1. Reduce the side effects associated with uterotonic drug use 2. Reduce the time to establishment and maintenance of adequate uterine tone

Conditions

  • Uterine Atony
  • Hypotension

Interventions

  • Oxytocin InfusionDrug

    500 mL bag of oxytocin (30 IU/500 mL) to be connected to the IV, and controlled per obstetrician request.

  • Oxytocin BolusDrug

    3 IU oxytocin and be given IV at time of baby delivery (Time 0). Up to two additional syringes can be given at 3 and 6 mins until uterine tone adequate (as per obstetrician on graded scale).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 1. Amount of Oxytocin to Obtain Satisfactory Uterine Tone.Time frame: Up to 15 min from time of infant delivery

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Brigham and Women's Hospital

    Boston, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.